AbbVie's 8.6% YoY revenue growth shows the business has successfully pivoted post-Humira, and adding a best-in-class atopic dermatitis asset in a $30B+ global market could extend that trajectory well into the next decade.

At 6.9% net margins and with a $10.9B all-cash outlay for a still-experimental drug, the deal math is difficult — AbbVie risks significant goodwill impairment and balance sheet stress if the asset fails to differentiate against Dupixent in late-stage trials.